ESPE2023 Poster Category 1 Fat, Metabolism and Obesity (97 abstracts)
1Weill Cornell Medicine-Qatar, Doha, Qatar. 2Sidra Medicine, Doha, Qatar
Background: Glucagon-like peptide-1 receptor (GLP-1R) agonists are approved for the treatment of T2DM and obesity and high dose liraglutide is FDA approved for chronic weight management in pediatric patients aged 12 and older who are obese. GLP-1R may also have a beneficial effect on the central and peripheral nervous system. Corneal Confocal Microscopy (CCM) has been used to show early nerve fiber regeneration in adults with obesity with and without diabetes.
Methods: Five obese children aged 14.2±1.9 years, weighing 101.86±7.83kg treated with Liraglutide 3.0mg daily underwent CCM to quantify corneal nerve fiber density (CNFD), branch density (CNBD) and length (CNFL) over 3 months.
Results: Despite no change in weight (101.86±7.83 vs. 103.28±7.26, P=0.14) or body fat percent (51.32±4.43 vs. 48.46±2.5, P=0.31), CNFD (24.37±2.72 vs. 30.29±4.1, P=0.017) and CNFL (15.75±2.88 vs. 17.91±1.35, P=0.046) improved significantly with no change in CNBD (29.17±13.23 vs. 28.72±7.02, P=0.944) over 3 months of Liraglutide treatment.
Conclusion: Corneal confocal microscopy identifies early corneal nerve regeneration after 3 months of Liraglutide treatment in obese children without diabetes. Liraglutide may induce nerve regeneration, independent of weight loss.